Sherry Adkins

3.5k total citations · 1 hit paper
14 papers, 2.1k citations indexed

About

Sherry Adkins is a scholar working on Oncology, Electrical and Electronic Engineering and Genetics. According to data from OpenAlex, Sherry Adkins has authored 14 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 4 papers in Electrical and Electronic Engineering and 3 papers in Genetics. Recurrent topics in Sherry Adkins's work include CAR-T cell therapy research (14 papers), Virus-based gene therapy research (3 papers) and Integrated Circuits and Semiconductor Failure Analysis (3 papers). Sherry Adkins is often cited by papers focused on CAR-T cell therapy research (14 papers), Virus-based gene therapy research (3 papers) and Integrated Circuits and Semiconductor Failure Analysis (3 papers). Sherry Adkins collaborates with scholars based in United States and India. Sherry Adkins's co-authors include Sattva S. Neelapu, Partow Kebriaei, Jason R. Westin, Nitin Jain, Katayoun Rezvani, Sudhakar Tummala, Yi Lin, Frederick L. Locke, Naval Daver and Alison Gulbis and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Nature Reviews Clinical Oncology.

In The Last Decade

Sherry Adkins

14 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

2017 1.6k citations Sattva S. Neelapu, Sudhakar Tummala et al. Nature Reviews Clinical Oncology profile →

Peers

Countries citing papers authored by Sherry Adkins

Since Specialization

Citations

This map shows the geographic impact of Sherry Adkins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sherry Adkins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sherry Adkins more than expected).

Fields of papers citing papers by Sherry Adkins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sherry Adkins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sherry Adkins. The network helps show where Sherry Adkins may publish in the future.

Co-authorship network of co-authors of Sherry Adkins

This figure shows the co-authorship network connecting the top 25 collaborators of Sherry Adkins. A scholar is included among the top collaborators of Sherry Adkins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sherry Adkins. Sherry Adkins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Factors associated with manufacturing failure of commercial CD19 CAR-T cell products for large b cell lymphoma (LBCL). 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), Jason R. Westin, Loretta J. Nastoupil, Ranjit Nair, Swaminathan P. Iyer, (unknown), Yago Nieto, Partow Kebriaei, Misha Hawkins, Dai Chihara, Luis Malpica, Sherry Adkins, Elizabeth J. Shpall, Jeremy Ramdial, Paolo Strati, Chitra Hosing, Sattva S. Neelapu, Sairah Ahmed	4
2	Use of Intrathecal Chemotherapy for Corticosteroid-Refractory Icans in B-Cell Lymphoma Patients Treated with CART 2024 ·Transplantation and Cellular Therapy ·Paolo Strati, Sandra Horowitz, (unknown), Ranjit Nair, Melody Becnel, Pavan Bachireddy, Swaminathan P. Iyer, (unknown), Sherry Adkins, Elizabeth J. Shpall, Jeremy Ramdial, Sattva S. Neelapu, Sairah Ahmed	1
3	Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS): A Review of Pharmacovigilance 2023 ·Blood ·(unknown), (unknown), Paolo Strati, Sairah Ahmed, Sherry Adkins, Samer A. Srour, Michael Wang, Preetesh Jain, Elizabeth J. Shpall, Anath C. Lionel, (unknown), Sattva S. Neelapu, Krina K. Patel, Swaminathan P. Iyer	2
4	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma 2020 ·Journal for ImmunoTherapy of Cancer ·Sattva S. Neelapu, Sherry Adkins, Stephen M. Ansell, Joshua Brody, Mitchell S. Cairo, Jonathan W. Friedberg, Justin Kline, Ronald Levy, David L. Porter, Koen van Besien, Michael E. Werner, Michael R. Bishop	11
5	Safety of CAR T-cell therapy in kidney transplant recipients 2020 ·Blood ·Omar Mamlouk, Ranjit Nair, Swaminathan P. Iyer, (unknown), Sattva S. Neelapu, Raphaël Steiner, Sherry Adkins, Misha Hawkins, Neeraj Saini, (unknown), Paolo Strati, Sreedhar Mandayam, Sairah Ahmed	38
6	Recognizing and Grading CAR T-Cell Toxicities: An Advanced Practitioner Perspective 2020 ·Frontiers in Oncology ·(unknown), Grace Watson, Swapna Johncy, Sherry Adkins	28
7	Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma 2020 ·Haematologica ·Paolo Strati, Ankur Varma, Sherry Adkins, Loretta J. Nastoupil, Jason R. Westin, Fredrick B. Hagemeister, Nathan Fowler, Hun Ju Lee, Luis Fayad, Felipe Samaniego, Sairah Ahmed, (unknown), Sandra Horowitz, (unknown), Swapna Johncy, Partow Kebriaei, Victor E. Mulanovich, Ella Ariza‐Heredia, Sattva S. Neelapu	94
8	Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma 2020 ·Blood Advances ·Chelsea C. Pinnix, Jillian R. Gunther, Bouthaina S. Dabaja, Paolo Strati, Penny Fang, Misha Hawkins, Sherry Adkins, Jason R. Westin, Sairah Ahmed, Luis Fayad, Hun Ju Lee, Ranjit Nair, Raphaël Steiner, Swaminathan P. Iyer, Maria Alma Rodriguez, Michael Wang, Christopher R. Flowers, Sattva S. Neelapu, Loretta J. Nastoupil	136
9	CAR T-Cell Therapy: Adverse Events and Management 2019 ·Journal of the Advanced Practitioner in Oncology ·Sherry Adkins	60
10	Hematopoietic recovery and immune reconstitution after axi-cel CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma. 2019 ·Journal of Clinical Oncology ·Paolo Strati, Sherry Adkins, Loretta J. Nastoupil, Jason R. Westin, Fredrick B. Hagemeister, Nathan Fowler, Hun Ju Lee, Luis Fayad, Felipe Samaniego, Sairah Ahmed, Ankur Varma, (unknown), Swapna Johncy, Partow Kebriaei, Victor E. Mulanovich, Ella Ariza‐Heredia, Sattva S. Neelapu	8
11	Comprehensive report of anti-CD19 chimeric antigen receptor T cells (CAR-T) associated non-relapse mortality (CART-NRM) from FAERS. 2019 ·Journal of Clinical Oncology ·Kartik Anand, Ethan Burns, (unknown), Sai Ravi Pingali, Jason R. Westin, Loretta J. Nastoupil, Hun Ju Lee, Felipe Samaniego, Simrit Parmar, Michael Wang, Misha Hawkins, Sherry Adkins, Luis Fayad, Raphaël Steiner, Ranjit Nair, Sairah Ahmed, Nathan Fowler, Sattva S. Neelapu, Swaminathan P. Iyer	3
12	CLINICAL IMPLICATIONS OF CYTOPENIAS BEYOND DAY 30 AFTER AXI‐CEL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA 2019 ·Hematological Oncology ·Paolo Strati, Sherry Adkins, (unknown), Jason R. Westin, (unknown), Nathan Fowler, (unknown), Luis Fayad, Felipe Samaniego, Saleem Ahmed, Ankur Varma, (unknown), Swapna Johncy, Partow Kebriaei, Victor E. Mulanovich, (unknown), (unknown)	1
13	Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL' 2018 ·Nature Reviews Clinical Oncology ·Sattva S. Neelapu, Sudhakar Tummala, Partow Kebriaei, William G. Wierda, Frederick L. Locke, Yi Lin, Nitin Jain, Naval Daver, Alison Gulbis, Sherry Adkins, Katayoun Rezvani, Patrick Hwu, Elizabeth J. Shpall	102
14	Chimeric antigen receptor T-cell therapy — assessment and management of toxicities breakdown → 2017 ·Nature Reviews Clinical Oncology ·Sattva S. Neelapu, Sudhakar Tummala, Partow Kebriaei, William G. Wierda, Cristina Gutiérrez, Frederick L. Locke, Krishna V. Komanduri, Yi Lin, Nitin Jain, Naval Daver, Jason R. Westin, Alison Gulbis, Monica Loghin, John de Groot, Sherry Adkins, Suzanne E. Davis, Katayoun Rezvani, Patrick Hwu, Elizabeth J. Shpall	1619

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact